McKesson completes US Oncology purchase for $2.2B

McKesson, a healthcare services and IT company, has completed its acquisition of US Oncology in a total transaction, including the assumption or repayment of the outstanding debt of US Oncology and its subsidiaries, which was valued at approximately $2.2 billion.

With the completion of the acquisition, initially announced Nov. 1, McKesson now delivers a set of oncology practice management offerings in the U.S. to help strengthen the financial performance of community oncologists and advance cancer care. According to the San Francisco-based company, oncologists will select from products and services, such as specialty distribution or inventory management technologies, or choose to become a strategic alliance customer, which provides technologies, practice management services and other resources for community oncologists.

The combined business will be led by Bruce Broussard, CEO of US Oncology, and will be headquartered in Woodlands, Texas, with continuing operations in the San Francisco Bay area and other locations throughout the U.S. Broussard now reports to Paul Julian, executive vice president and group president at McKesson.

 

Around the web

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services.